Octreotide for the treatment of sulfonylurea poisoning

References

• Natahn DM, Rousell A, Godine JE. Glyburide or insulin form metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Ann Intern Med 1988; 108:334–340.
   PubMed Web of Science ®Google Scholar
• Harrigan RA, Nathan MS, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 2001; 38:68–78.
   PubMed Web of Science ®Google Scholar
• Abrahamsson H, Berggren PO, Rorsman P. Direct measurement of increased free cytoplasmic Ca2+ in mouse pancreatic beta-cells following stimulation by hypoglycemic sulfonylureas. FEBS Lett 1985; 190:21–24.
   PubMed Web of Science ®Google Scholar
• Spiller HA. Management of sulfonylurea ingestion. Pediat Emerg Care 1999; 15:227–230.
   PubMed Web of Science ®Google Scholar
• Bosse GM. Antidiabetics and hypoglycemia. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE, eds. Goldfrank's Toxicologic Emergencies. 9th ed. New York: McGraw-Hill; 2011:714–727.
   Google Scholar
• Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231–1245.
   PubMed Web of Science ®Google Scholar
• Das AK, Shah S. History of diabetes: from ants to analogs. J Assoc Physicians India 2011; 59(Suppl):6–7.
   PubMedGoogle Scholar
• Nagasawa HT, DeMaster EG, Kwon CH, Fraser PS, Shirota FN. Structure vs. activity in the sulfonylurea-mediated disulfiram-ethanol reaction. Alcohol 1985; 2:123–128.
   PubMed Web of Science ®Google Scholar
• Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS. Glipizide: a review of its pharmacological properties and therapeutic use. Drugs 1979; 18:329–353.
   PubMed Web of Science ®Google Scholar
• Prendergast BD. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm 1984; 3:473–485.
   PubMedGoogle Scholar
• Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes 2004; 53(Suppl 3):S151–S155.
   PubMedGoogle Scholar
• AHFS Drug Information. American Hospital Formulary Service Board of the American Society of Health System Pharmacists 1998;68:2595–2597.
   Google Scholar
• Hussain K, Mundi H, Aynsley-Green A, Champion M. A child presenting with disordered consciousness, hallucinations, screaming episodes and abdominal pain. Eur J Pediatr 2002; 161:127–129.
   PubMed Web of Science ®Google Scholar
• Matteucci MJ. One pill can kill: assessing the potential for fatal poisonings in children. Pediatr Ann 2005; 34:964–968.
   PubMed Web of Science ®Google Scholar
• Little GL, Boniface KS. Are one or two dangerous? Sulfonylurea exposure in toddlers. J Emerg Med 2005; 28:305–310.
   PubMed Web of Science ®Google Scholar
• Glatstein M, Garcia-Bournissen F, Scolnik D, Koren G, Finkelstein Y. Hypoglycemia in a healthy toddler. Ther Drug Monit 2009; 31: 173–177.
   PubMed Web of Science ®Google Scholar
• Glatstein M, Garcia-Bournissen F, Scolnik D, Koren G. Sulfonylurea intoxication at a tertiary care paediatric hospital. Can J Clin Pharmacol 2010; 17:e51–6.
   PubMedGoogle Scholar
• Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AC, Wruk KM. 2005 Annual Report of the American Association of Poison Control Centers’ national poisoning and exposure database. Clin Toxicol 2006; 44:803–932.
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr., Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol 2011; 49:910–941.
   PubMed Web of Science ®Google Scholar
• Burge MR, Schmitz-Fiorentino K, Fischette C, Qualls CR, Schade DS. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 1998; 279:137–143.
   PubMed Web of Science ®Google Scholar
• Owen L, Ellis M, Shield J. Deliberate sulphonylurea poisoning mimicking hyperinsulinaemia of infancy. Arch Dis Child 2000; 82: 392–393.
   PubMed Web of Science ®Google Scholar
• Vialettes B, Vague P. The clinical value of C-peptide assay. Diabetes Metab 1980; 6:225–229.
   Web of Science ®Google Scholar
• Lheureux PE, Zahir S, Penaloza A, Gris M. Bench-to bedside review: antidotal treatment of sulphonylurea-induced hypoglycaemia with octreotide. Crit Care 2005; 9:543–549.
   PubMed Web of Science ®Google Scholar
• Johnson SF, Schade DS, Peake GT. Chlorpropamide-induced hypoglycemia: successful treatment with diazoxide. Am J Med 1977; 63:799–804.
   PubMed Web of Science ®Google Scholar
• Graudins A, Linden CH, Ferm RP. Diagnosis and treatment of sulphonylurea-induced hyperinsulinaemic hypoglycemia. Am J Emerg Med 1997; 15:95–96.
   PubMed Web of Science ®Google Scholar
• Katz MD, Erstad BL. Octreotide, a new somatostain analogue. Clin Pharm 1989; 8:255–273.
   PubMedGoogle Scholar
• Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 2003; 55:105–131.
   PubMed Web of Science ®Google Scholar
• Azkur D, Yoldas T, Toyran M, Kocabas CN. A pediatric case of anaphylaxis due to octreotide. Asian Pac J Allergy Immunol 2011; 29:361–363.
   PubMed Web of Science ®Google Scholar
• Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, Lamberts SW. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 2005; 78:69–80.
   PubMed Web of Science ®Google Scholar
• Gregersen T, Grønbæk H, Worsøe J, Schlageter V, Laurberg S, Krogh K. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. Scand J Gastroenterol 2011; 46:895–902.
   PubMed Web of Science ®Google Scholar
• Thompson CS, O'Dorisio TM, Woltering EA. Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma. Digestion 1996; 57(Suppl 1):62–68.
   PubMedGoogle Scholar
• Howland MA. Octreotide. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE, eds. Goldfrank's toxicologic emergencies. 9th ed. New York: McGraw-Hill; 2011: 734–737.
   Google Scholar
• Kutz K, Nüesch E, Rosenthaler J. Pharmacokinetics of SMS 201–995 in healthy subjects. Scand J Gastroenterol Suppl 1986; 119:65–72.
   PubMedGoogle Scholar
• Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res 2005; 15:200–206.
   PubMed Web of Science ®Google Scholar
• McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003; 3:2473–2499.
   Google Scholar
• Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993; 25:375–391.
   PubMed Web of Science ®Google Scholar
• Sakurai H, Dobbs R, Unger RH. Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs. J Clin Invest 1974; 54:1395–1402.
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, . SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31:1133–1140.
   PubMed Web of Science ®Google Scholar
• Gul M, Cander B, Girisgin S, Ayan M, Kocak S, Unlu A. The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose. Adv Ther 2006; 23:878–884.
   PubMed Web of Science ®Google Scholar
• Gerich JE, Lorenzi M, Schneider V, Forsham PH. Effect of somatostatin on plasma glucose and insulin responses to glucagon and tolbutamide in man. J Clin Endocrinol Metab 1974; 39:1057–1060.
   PubMed Web of Science ®Google Scholar
• Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993; 76:752–756.
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Boyle PJ, Macdonald LM, Schade DS. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994; 43:24–31.
   PubMed Web of Science ®Google Scholar
• Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, Häring HU. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 2002; 25:2065–2073.
   PubMed Web of Science ®Google Scholar
• Phillips RE, Warrell DA, Looareesuwan S, Turner RC, Bloom SR, Quantrill D, Moore AR. Effectiveness of SMS 201–995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia. Lancet 1986; 1:713–716.
   PubMed Web of Science ®Google Scholar
• Lee PE, Meneilly GS. The effect of octreotide on glucose and insulin levels in a patient with type 2 diabetes on glibenclamide. Diabetes Metab 1999; 25:347–349.
   PubMed Web of Science ®Google Scholar
• Gardner-Roehnelt NM. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects. Clin J Oncol Nurs 2012; 16:56–64.
   PubMed Web of Science ®Google Scholar
• Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Eng J Med 1996; 334:246–254.
   PubMed Web of Science ®Google Scholar
• Losa M, Mortini P, Giovanelli M. The role of somatostatin analogues in the treatment of hypophyseal adenomas. Minerva Endocrinol 2003; 28:39–51.
   PubMedGoogle Scholar
• Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellanné-Chantelot C, Valayannopoulos V, . Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol 2012; 166:333–339.
   PubMed Web of Science ®Google Scholar
• Rath S, Bar-Zeev N, Anderson K, Fahy R, Roseby R. Octreotide in children with hypoglycaemia due to sulfonylurea ingestion. J Paediatr Child Health 2008; 44:383–384.
   PubMed Web of Science ®Google Scholar
• Kent DA, Main BA, Friesen MS. Use of octreotide in sulfonylurea poisoning in a child. J Toxicol Clin Toxicol 2003; 41:669 (abstract).
   Google Scholar
• Mordel A, Sivilotti MLA, Old AC, Ferm RP. Octreotide for pediatric sulphonylurea poisoning. J Toxicol Clin Toxicol 1998; 36:437 (abstract).
   Google Scholar
• Pelavin PI, Abramson E, Pon S, Vogiatzi MG. Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide. J Pediatr Endocrinol Metab 2009; 22:171–175.
   PubMed Web of Science ®Google Scholar
• Calello DP, Osterhoudt KC, Henretig FM, Perrone J. Octreotide for pediatric sulfonylurea overdose: review of 5 cases. Clin Toxicol 2005; 43:671 (abstract).
   Web of Science ®Google Scholar
• Calello DP, Kelly A, Osterhoudt KC. Case files of the Medical Toxicology Fellowship Training Program at the Children's Hospital of Philadelphia: a pediatric exploratory sulfonylurea ingestion. J Med Toxicol 2006; 2:19–24.
   PubMedGoogle Scholar
• Soderstrom J, Murray L, Daly FFS, Little M. Toxicology case of the month: oral hypoglycaemic overdose. Emerg Med J 2006; 23:565–567.
   PubMed Web of Science ®Google Scholar
• Fasano CJ, O'Malley G, Dominici P, Aguilera E, Latta DR. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51:400–406.
   PubMed Web of Science ®Google Scholar
• McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med 2000; 36:133–138.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Skugor M, Chinnappa P, Siraj ES. Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr Pract 2006; 12:635–640.
   PubMedGoogle Scholar
• Adabala M, Jhaveri KD, Gitman M. Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant 2010; 25:3439–3442.
   PubMed Web of Science ®Google Scholar
• Hung O, Eng J, Ho J, Aks S, Howland M, Erickson T, Hoffman R. Octreotide as an antidote for refractory sulfonylurea hypoglycemia. J Toxicol Clin Toxicol 1997; 35:540–541 (abstract).
   Google Scholar
• Vallurupalli S. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure. Ann Pharmacother 2010; 44:387–390.
   PubMed Web of Science ®Google Scholar
• Green RS, Palatnick W. Effectiveness of octreotide in a case of refractory sulfonylurea-induced hypoglycemia. J Emerg Med 2003; 25:283–287.
   PubMed Web of Science ®Google Scholar
• Braatvedt GD. Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes. N Z Med J 1997; 110:189–190.
   PubMedGoogle Scholar
• Bui L, Adler D, Keller KH. Prolonged octreotide infusion to treat glyburide-induced hypoglycemia. J Toxicol Clin Toxicol 2000; 38: 576 (abstract).
   Google Scholar
• Carr R, Zed PJ. Octreotide for sulfonylurea-induced hypoglycemia following overdose. Ann Pharmacother 2002; 36:1727–1732.
   PubMed Web of Science ®Google Scholar
• Crawford BAL, Perera C. Octreotide treatment for sulfonylurea-induced hypoglycemia. Med J Aust 2004; 180:540–541.
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Boyle PJ, Justice KM, Wright AD, Schade DS. Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide. Diabetes Care 1993; 16:184–186.
   PubMed Web of Science ®Google Scholar
• Nzerue CM, Thomas J, Volcy J, Edeki T. Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure. Int J Artif Organs 2003; 26:86–89.
   PubMed Web of Science ®Google Scholar
• Gonzalez RR, Zweig S, Rao J, Block R, Greene LW. Octreotide therapy for recurrent refractory hypoglycemia due to sulfonylurea in diabetes-related kidney failure. Endocr Pract 2007; 13:417–423.
   PubMedGoogle Scholar
• Hanchard B, Boulouffe C, Vanpee D. Sulfonylurea-induced hypoglycaemia: use of octreotide. Acta Clin Belg 2009; 64:56–58.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Canseco E. Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect. Am J Med 2010; 123:e5–6
   PubMedGoogle Scholar
• Hung WP, Wang JN, Chang HK, Wu JM. Octreotide therapy in two children with intractable postoperative chylothorax. Int J Cardiol 2011; 146:e63–65.
   PubMed Web of Science ®Google Scholar